Soliqua 100 33 for basal patients?

Soliqua 100/33 is a fixed‑dose daily injection that combines insulin glargine (a long-acting basal insulin) with lixisenatide (a GLP-1 receptor agonist).

- Who it’s for: Adults with type 2 diabetes not adequately controlled on basal insulin alone or on lixisenatide alone. Not for type 1 diabetes or DKA. It’s also not recommended if you have a personal or family history of medullary thyroid carcinoma or MEN2, or if you have pancreatitis or certain other conditions.

- How it works for basal patients: You switch from daily basal insulin to Soliqua, which provides both basal insulin and GLP-1RA effects in one daily shot.

- Starting dose (for basal patients): 15 units once daily. This provides 15 units of insulin glargine and a small fixed amount of lixisenatide. Take it at the same time each day (any time of day, but keep it consistent).

- Titration: Increase by 15 units every 3–4 days based on fasting blood glucose and tolerability, up to a maximum of 60 units per day. The goal is to reach your target fasting glucose without causing hypoglycemia.

- Important notes:
- Do not use Soliqua if you have type 1 diabetes or diabetic ketoacidosis.
- If you were on a higher dose of basal insulin, Soliqua is designed to replace that insulin dose up to 60 units/day; your clinician will guide the exact plan.
- Side effects can include nausea, vomiting, diarrhea, and risk of hypoglycemia. GI symptoms often improve over time.
- It should be injected under the skin (abdomen, thigh, or upper arm) once daily.
- Keep to a consistent daily dosing time; store per product guidance (typically refrigerated until first use; after starting, can be kept at room temperature for a few weeks).

If you’d like, tell me your current basal insulin dose, your target fasting glucose, kidney function, and any other meds you’re taking. I can help you think through a rough titration plan and what to discuss with your clinician. This is general information and not medical advice.